Use of liposomes as drug delivery vehicles for treatment of melanoma

Pigment Cell and Melanoma Research

Volumn 22, Issue 4, 2009, Pages 388-399

  Tran, Melissa A ^a   Watts, Rebecca J ^a   Robertson, Gavin P ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Antibodies; Chemotherapy; Liposomes; Melanoma; SiRNA

Indexed keywords

1,2 DIMYRISTYLOXYPROPYL 3 DIMETHYLHYDROXYETHYLAMMONIUM BROMIDE; 1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 4 S CYSTEAMINYLPHENOL; ALLOVECTIN 7; ALPHA INTERFERON; BISMUTH 213; BLEOMYCIN; CERAMIDE; CHOLESTEROL; CYCLOPHOSPHAMIDE; DACARBAZINE; DIOLEOYLPHOSPHATIDYLCHOLINE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DIPALMITOYLPHOSPHATIDYLGLYCEROL; DOXORUBICIN; HISTIDINE (N,N DI N HEXADECYLAMINE)ETHYLAMIDE; INTERLEUKIN 2; LUCIFERASE; MELAN A; MESSENGER RNA; MYC PROTEIN; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE N [METHOXY(POLYETHYLENE GLYCOL) 2000]; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SORAFENIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; CANCER PATIENT; CIRCULATION TIME; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EARLY DIAGNOSIS; HUMAN; LIPOSOMAL DELIVERY; LONG TERM CARE; MELANOMA; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; RETICULOENDOTHELIAL SYSTEM; REVIEW; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; DRUG COMPOUNDING; GENE THERAPY; HUMANS; LIPOSOMES; MELANOMA; NANOSTRUCTURES; NUCLEIC ACIDS; SKIN NEOPLASMS;

EID: 67749135874     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2009.00581.x     Document Type: Review

References (130)

1. Aagaard, L. Rossi, J.J. (2007). RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 59, 75 86.
2. Aigner, A. (2007). Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl. Microbiol. Biotechnol. 76, 9 21.
3. Akhtar, S. Benter, I.F. (2007). Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 117, 3623 3632.
4. Allen, B.J., Rizvi, S.M. Tian, Z. (2001). Preclinical targeted alpha therapy for subcutaneous melanoma. Melanoma Res. 11, 175 182.
5. Altomare, D.A. Testa, J.R. (2005). Perturbations of the AKT signaling pathway in human cancer. Oncogene 24, 7455 7464.
6. Balch, C.M. (1998). Cutaneous Melanoma, 3rd edn (St. Louis, Mo : Quality Medical Pub).
7. di Bartolomeo, S. Spinedi, A. (2001). Differential chemosensitizing effect of two glucosylceramide synthase inhibitors in hepatoma cells. Biochem. Biophys. Res. Commun. 288, 269 274.
8. Batist, G., Ramakrishnan, G., Rao, C.S. et al. (2001). Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 19, 1444 1454.
9. Behlke, M.A. (2006). Progress towards in vivo use of siRNAs. Mol. Ther. 13, 644 670.
10. Berd, D., Herlyn, M., Koprowski, H. Mastrangelo, M.J. (1989). Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens. Cancer Res. 49, 6840 6844.
11. Besic, E. (2007). Physical mechanisms and methods employed in drug delivery to tumors. Acta Pharm. 57, 249 268.
12. Bianco, A., Kostarelos, K., Partidos, C.D. Prato, M. (2005). Biomedical applications of functionalised carbon nanotubes. Chem. Commun. (Camb) 5, 571 577. (Pubitemid 40299037)
13. Brose, M.S., Volpe, P., Feldman, M. et al. (2002). BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62, 6997 7000.
14. Brummelkamp, T.R., Bernards, R. Agami, R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550 553.
15. Byrne, C.M., Thompson, J.F., Johnston, H., Hersey, P., Quinn, M.J., Michael Hughes, T. McCarthy, W.H. (2005). Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res. 15, 45 51.
16. Chang, D.K., Lin, C.T., Wu, C.H. Wu, H.C. (2009). A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS ONE 4, e4171.
17. Chen, A.A., Derfus, A.M., Khetani, S.R. Bhatia, S.N. (2005). Quantum dots to monitor RNAi delivery and improve gene silencing. Nucleic Acids Res. 33, e190.
18. Cheung, M., Sharma, A., Madhunapantula, S.V. Robertson, G.P. (2008). Akt3 and mutant (V600E) B-Raf cooperate to promote early melanoma development. Cancer Res. 68, 3429 3439.
19. Chien, P.Y., Wang, J., Carbonaro, D., Lei, S., Miller, B., Sheikh, S., Ali, S.M., Ahmad, M.U. Ahmad, I. (2005). Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther. 12, 321 328.
20. Cuenca, A.G., Jiang, H., Hochwald, S.N., Delano, M., Cance, W.G. Grobmyer, S.R. (2006). Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 107, 459 466.
21. Dai, Y., Yu, C., Singh, V., Tang, L., Wang, Z., McInistry, R., Dent, P. Grant, S. (2001). Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 61, 5106 5115.
22. Daniel, C.W. Smith, G.H. (1999). The mammary gland: a model for development. J. Mammary Gland Biol. Neoplasia 4, 3 8.
23. Danielson, K.G., Oborn, C.J., Durban, E.M., Butel, J.S. Medina, D. (1984). Epithelial mouse mammary cell line exhibiting normal morphogenesis in vivo and functional differentiation in vitro. Proc. Natl. Acad. Sci. U S A 81, 3756 3760.
24. Davies, H., Bignell, G.R., Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949 954.
25. DeJong, W.H. Borm, P.J. (2008). Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 3, 133.
26. Del Vecchio, S., Reynolds, J.C., Carrasquillo, J.A., Blasberg, R.G., Neumann, R.D., Lotze, M.T., Bryant, G.J., Farkas, R.J. Larson, S.M. (1989). Local distribution and concentration of intravenously injected 131I-9.2.27 monoclonal antibody in human malignant melanoma. Cancer Res. 49, 2783 2789.
27. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K. Tuschl, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494 498.
28. Elder, D. (1999). Tumor progression, early diagnosis and prognosis of melanoma. Acta Oncol. 38, 535 547.
29. Elder, D.E., Clark, W.H. Jr., Elenitsas, R., Guerry, D.t. Halpern, A.C. (1993). The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi. Semin. Diagn. Pathol. 10, 18 35.
30. Ellerhorst, J.A., Bedikian, A., Ring, S., Buzaid, A.C., Eton, O. Legha, S.S. (1999). Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. Oncol. Rep. 6, 1097 1099.
31. Elwood, J.M. Jopson, J. (1997). Melanoma and sun exposure: an overview of published studies. Int. J. Cancer 73, 198 203.
32. Farhood, H., Serbina, N. Huang, L. (1995). The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta 1235, 289 295.
33. Foster, L.J., Li, D., Randhawa, V.K. Klip, A. (2001). Insulin accelerates inter-endosomal GLUT4 traffic via phosphatidylinositol 3-kinase and protein kinase B. J. Biol. Chem. 276, 44212 44221.
34. Franke, T.F., Yang, S.I., Chan, T.O., Datta, K., Kazlauskas, A., Morrison, D.K., Kaplan, D.R. Tsichlis, P.N. (1995). The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81, 727 736.
35. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A. Barenholz, Y. (1994). Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54, 987 992.
36. Gandini, S., Sera, F., Cattaruzza, M.S., Pasquini, P., Zanetti, R., Masini, C., Boyle, P. Melchi, C.F. (2005). Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur. J. Cancer 41, 2040 2059.
37. Garbe, C. Eigentler, T.K. (2007). Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 17, 117 127.
38. Gokhale, P.C., Zhang, C., Newsome, J.T., Pei, J., Ahmad, I., Rahman, A., Dritschilo, A. Kasid, U.N. (2002). Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin. Cancer Res. 8, 3611 3621.
39. Grandage, V.L., Gale, R.E., Linch, D.C. Khwaja, A. (2005). PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 19, 586 594.
40. Gray, M.J., Van Buren, G., Dallas, N.A. et al. (2008). Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J. Natl Cancer Inst. 100, 109 120.
41. Guerry, D., Synnestvedt, M., Elder, D.E. Schultz, D. (1993). Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J. Invest. Dermatol. 100, 342S 345S.
42. Gullick, W.J. (1991). Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull. 47, 87 98.
43. Halder, J., Kamat, A.A., Landon, C.N. Jr. et al. (2006). Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res. 12, 4916 4924.
44. Harding, C., Heuser, J. Stahl, P. (1983). Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 97, 329 339.
45. Hashida, M., Kawakami, S. Yamashita, F. (2005). Lipid carrier systems for targeted drug and gene delivery. Chem. Pharm. Bull. (Tokyo) 53, 871 880.
46. Hilgenbrink, A.R. Low, P.S. (2005). Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci. 94, 2135 2146.
47. Hingorani, S.R., Jacobetz, M.A., Robertson, G.P., Herlyn, M. Tuveson, D.A. (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63, 5198 5202.
48. Hirsch, L.R., Stafford, R.J., Bankson, J.A., Sershen, S.R., Rivera, B., Price, R.E., Hazle, J.D., Halas, N.J. West, J.L. (2003). Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl. Acad. Sci. U S A 100, 13549 13554.
49. Hosgood, G. Hoskins, J.D. (1998). Small Animal Paediatric Medicine and Surgery (Woburn, MA : Butterworth-Heinemann).
50. Ito, A., Fujioka, M., Yoshida, T., Wakamatsu, K., Ito, S., Yamashita, T., Jimbow, K. Honda, H. (2007). 4-S-Cysteaminylphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma. Cancer Sci. 98, 424 430.
51. Kane, R.C., Farrell, A.T., Saber, H. et al. (2006). Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res. 12, 7271 7278.
52. Kaushik, S., Hord, A.H., Denson, D.D., McAllister, D.V., Smitra, S., Allen, M.G. Prausnitz, M.R. (2001). Lack of pain associated with microfabricated microneedles. Anesth. Analg. 92, 502 504.
53. Kawakami, S. Hashida, M. (2007). Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab. Pharmacokinet. 22, 142 151.
54. Kawamori, T., Osta, W., Johnson, K.R. et al. (2006). Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J. 20, 386 388.
55. Keer, H.N., Kozlowski, J.M., Tsai, Y.C., Lee, C., McEwan, R.N. Grayhack, J.T. (1990). Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J. Urol. 143, 381 385.
56. Kim, D.H. Rossi, J.J. (2007). Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8, 173 184.
57. Landon, C.N. Jr., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M.T., Lopez-Berestein, G. Sood, A.K. (2005). Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910 6918.
58. Lee, T.Y., Lin, C.T., Kuo, S.Y., Chang, D.K. Wu, H.C. (2007). Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res. 67, 10958 10965.
59. Liu, Y., Miyoshi, H. Nakamura, M. (2007). Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int. J. Cancer 120, 2527 2537.
60. Loo, C., Lin, A., Hirsch, L., Lee, M.H., Barton, J., Halas, N., West, J. Drezek, R. (2004). Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol. Cancer Res. Treat 3, 33 40.
61. Lopez-Bergami, P., Fitchman, B. Ronai, Z. (2008). Understanding signaling cascades in melanoma. Photochem. Photobiol. 84, 289 306.
62. Lv, H., Zhang, S., Wang, B., Cui, S. Yan, J. (2006). Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control Release 114, 100 109.
63. Madhankumar, A.B., Slagle-Webb, B., Mintz, A., Sheehan, J.M. Connor, J.R. (2006). Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol. cancer ther. 5, 3162 3169.
64. Madhunapantula, S.V. Robertson, G.P. (2008). Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res. 68, 5 8.
65. Mathias, S., Pena, L.A. Kolesnick, R.N. (1998). Signal transduction of stress via ceramide. Biochem. J. 335 (Pt 3 465 480.
66. Mattes, M.J., Major, P.P., Goldenberg, D.M., Dion, A.S., Hutter, R.V. Klein, K.M. (1990). Patterns of antigen distribution in human carcinomas. Cancer Res. 50, 880s 884s.
67. McDonald, D.M. Baluk, P. (2002). Significance of blood vessel leakiness in cancer. Cancer Res. 62, 5381 5385.
68. Mehier-Humbert, S., Bettinger, T., Yan, F. Guy, R.H. (2005). Ultrasound-mediated gene delivery: kinetics of plasmid internalization and gene expression. J. Control Release 104, 203 211.
69. Merritt, W.M., Lin, Y.G., Spannuth, W.A. et al. (2008). Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J. Natl Cancer Inst. 100, 359 372.
70. Mezei, M. Gulasekharam, V. (1980). Liposomes - a selective drug delivery system for the topical route of administration. Lotion dosage form. Life Sci. 26, 1473 1477.
71. Miller, C.J., Cheung, M., Sharma, A., Clarke, L., Helm, K., Mauger, D. Robertson, G.P. (2004). Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J. Invest. Dermatol. 123, 990 992.
72. Mir, L.M., Glass, L.F., Sersa, G. et al. (1998). Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br. J. Cancer 77, 2336 2342.
73. Mitragotri, S. Kost, J. (2004). Low-frequency sonophoresis: a review. Adv. Drug. Deliv. Rev. 56, 589 601.
74. Mockey, M., Bourseau, E., Chandrashekhar, V., Chaudhuri, A., Lafosse, S., Le Cam, E., Quesniaux, V.F., Ryffel, B., Pichon, C. Midoux, P. (2007). mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Ther. 14, 802 814.
75. Na, K., Lee, K.H., Lee, D.H. Bae, Y.H. (2006). Biodegradable thermo-sensitive nanoparticles from poly(L-lactic acid)/poly(ethylene glycol) alternating multi-block copolymer for potential anti-cancer drug carrier. Eur. J. Pharm. Sci. 27, 115.
76. Nie, S., Xing, Y., Kim, G.J. Simons, J.W. (2007). Nanotechnology applications in cancer. Annu. Rev. Biomed. Eng. 9, 257 288.
77. Nogawa, M., Yuasa, T., Kimura, S. et al. (2005). Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J. Clin. Invest. 115, 978 985.
78. Okumura, K., Nakase, M., Inui, M., Nakamura, S., Watanabe, Y. Tagawa, T. (2008). Bax mRNA therapy using cationic liposomes for human malignant melanoma. J.Gene Med. 10, 910 917.
79. Paddison, P.J., Caudy, A.A., Bernstein, E., Hannon, G.J. Conklin, D.S. (2002). Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16, 948 958.
80. Pal, A., Ahmad, A., Khan, S., Sakabe, I., Zhang, C., Kasid, U.N. Ahmad, I. (2005). Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int. J. Oncol. 26, 1087 1091.
81. Panka, D.J., Atkins, M.B. Mier, J.W. (2006). Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin. Cancer Res. 12, 2371s 2375s.
82. Pantarotto, D., Briand, J.P., Prato, M. Bianco, A. (2004). Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chem. Commun. (Camb) 1, 16 17.
83. Pastorino, F., Brignole, C., Marimpietri, D., Pagnan, G., Morando, A., Ribatti, D., Semple, S.C., Gambini, C., Allen, T.M. Ponzoni, M. (2003). Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin. Cancer Res. 9, 4595 4605.
84. Peer, D., Park, E.J., Morishita, Y., Carman, C.V. Shimaoka, M. (2008). Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science (New York, NY) 319, 627 630.
85. del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. Nunez, G. (1997). Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687 689.
86. Petri-Fink, A., Chastellain, M., Juillerat-Jeanneret, L., Ferrari, A. Hofmann, H. (2005). Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells. Biomaterials 26, 2685 2694.
87. Pluschke, G., Vanek, M., Evans, A., Dittmar, T., Schmid, P., Itin, P., Filardo, E.J. Reisfeld, R.A. (1996). Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc. Natl. Acad. Sci. U S A 93, 9710 9715.
88. Radin, N.S. (2001). Killing cancer cells by poly-drug elevation of ceramide levels: a hypothesis whose time has come? Eur. J. Biochem. 268, 193 204.
89. Reintgen, D.S., McCarty, K.M. Jr., Cox, E. Seigler, H.F. (1982). Malignant melanoma in black American and white American populations. A comparative review. JAMA 248, 1856 1859.
90. Rizvi, S.M., Qu, C.F., Song, Y.J., Raja, C. Allen, B.J. (2005). In vivo studies of pharmacokinetics and efficacy of Bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27. Cancer Biol. Ther. 4, 763 768.
91. Robertson, G.P. (2005). Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev. 24, 273 285.
92. Santel, A., Aleku, M., Keil, O. et al. (2006). RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther. 13, 1360 1370.
93. Schumacher, R., Amacker, M., Neuhaus, D., Rosenthal, R., Groeper, C., Heberer, M., Spagnoli, G.C., Zurbriggen, R. Adamina, M. (2005). Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro. Vaccine 23, 5572 5582.
94. Seib, F.P., Jones, A.T. Duncan, R. (2007). Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10 melanoma cells. J. Control Release 117, 291 300.
95. Seydel, C. (2003). Quantum dots get wet. Science 300, 80 81.
96. Shabbits, J.A. Mayer, L.D. (2003a). High ceramide content liposomes with in vivo antitumor activity. Anticancer Res. 23, 3663 3669.
97. Shabbits, J.A. Mayer, L.D. (2003b). Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim. Biophys. Acta 1612, 98 106.
98. Shankar, P., Manjunath, N. Lieberman, J. (2005). The prospect of silencing disease using RNA interference. JAMA 293, 1367 1373.
99. Sharma, A., Trivedi, N.R., Zimmerman, M.A., Tuveson, D.A., Smith, C.D. Robertson, G.P. (2005). Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65, 2412 2421.
100. Sharma, A., Tran, M.A., Liang, S., Sharma, A.K., Amin, S., Smith, C.D., Dong, C. Robertson, G.P. (2006). Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase in the mutant (v600e) b-raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res. 66, 8200 8209.
101. Shiku, H., Takahashi, T. Oettgen, H.F. (1976). Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens. J. Exp. Med. 144, 873 881.
102. Shiraga, E., Barichello, J.M., Ishida, T. Kiwada, H. (2008). A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model. Int. J. Pharm. 353, 65.
103. Singh, M. (1999). Transferrin as A targeting ligand for liposomes and anticancer drugs. Curr. Pharm. Des. 5, 443 451.
104. Singh, R., Pantarotto, D., McCarthy, D., Chaloin, O., Hoebeke, J., Partidos, C.D., Briand, J.P., Prato, M., Bianco, A. Kostarelos, K. (2005). Binding and condensation of plasmid DNA onto functionalized carbon nanotubes: toward the construction of nanotube-based gene delivery vectors. J. Am. Chem. Soc. 127, 4388 4396.
105. Sinico, C., Manconi, M., Peppi, M., Lai, F., Valenti, D. Fadda, A.M. (2005). Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle-skin interaction. J. Control Release 103, 123 136.
106. Smylie, M.G., Wong, R., Mihalcioiu, C., Lee, C. Pouliot, J. (2007). A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma. Invest. New Drugs 25, 155.
107. Stahl, J.M., Cheung, M., Sharma, A., Trivedi, N.R., Shanmugam, S. Robertson, G.P. (2003). Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 63, 2881 2890.
108. Stahl, J.M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J.Q., Bosenberg, M.W., Kester, M., Sandirasegarane, L. Robertson, G.P. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 7002 7010.
109. Stover, T. Kester, M. (2003). Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J. Pharmacol. Exp. Ther. 307, 468 475.
110. Stover, T.C., Sharma, A., Robertson, G.P. Kester, M. (2005). Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin. Cancer Res. 11, 3465 3474.
111. Strieth, S., Eichhorn, M.E., Werner, A., Sauer, B., Teifel, M., Michaelis, U., Berghaus, A. Dellian, M. (2008). Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin. Clinical Cancer Res. 14, 4603 4611.
112. Suzuki, R., Takizawa, T., Negishi, Y., Utoguchi, N., Sawamura, K., Tanaka, K., Namai, E., Oda, Y., Matsumura, Y. Maruyama, K. (2008). Tumor specific ultrasound enhanced gene transfer in vivo with novel liposomal bubbles. J. Control Release 125, 137 144.
113. Tasciotti, E., Liu, X., Bhavane, R. et al. (2008). Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. nanotechnol. 3, 151 157.
114. Toker, A. Yoeli-Lerner, M. (2006). Akt signaling and cancer: surviving but not moving on. Cancer Res. 66, 3963 3966.
115. Tran, M.A., Gowda, R., Sharma, A., Park, E.J., Adair, J., Kester, M., Smith, N.B. Robertson, G.P. (2008a). Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res. 68, 7638 7649.
116. Tran, M.A., Smith, C.D., Kester, M. Robertson, G.P. (2008b). Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin. Cancer Res. 14, 3571 3581.
117. Treat, J., Damjanov, N., Huang, C., Zrada, S. Rahman, A. (2001). Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology (Williston Park) 15, 44 48.
118. Tuveson, D.A., Weber, B.L. Herlyn, M. (2003). BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4, 95 98.
119. Verma, U.N., Surabhi, R.M., Schmaltieg, A., Becerra, C. Gaynor, R.B. (2003). Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin. Cancer Res. 9, 1291 1300.
120. Villares, G.J., Zigler, M., Wang, H. et al. (2008). Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 68, 9078 9086.
121. Vorhies, J.S. Nemunaitis, J. (2007). Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies. Expert Rev. Anticancer Ther. 7, 373 382.
122. Waldmann, V., Wacker, J. Deichmann, M. (2002). Absence of mutations in the pleckstrin homology (PH) domain of protein kinase B (PKB/Akt) in malignant melanoma. Melanoma Res. 12, 45 50.
123. Wang, F., Van Brocklyn, J.R., Hobson, J.P., Movafagh, S., Zukowska-Grojec, Z., Milstien, S. Spiegel, S. (1999). Sphingosine 1-phosphate stimulates cell migration through a G(i)-coupled cell surface receptor. Potential involvement in angiogenesis. J. Biol. Chem. 274, 35343 35350.
124. Wang, M.D., Shin, D.M., Simons, J.W. Nie, S. (2007a). Nanotechnology for targeted cancer therapy. Expert Rev. Anticancer Ther. 7, 833 837.
125. Wang, Q., Ilves, H., Chu, P., Contag, C.H., Leake, D., Johnston, B.H. Kaspar, R.L. (2007b). Delivery and inhibition of reporter genes by small interfering rnas in a mouse skin model. J. Invest. Dermatol. 127, 2577 2584.
126. Wu, X., Liu, H., Liu, J., Haley, K.N., Treadway, J.A., Larson, J.P., Ge, N., Peale, F. Bruchez, M.P. (2003). Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat. Biotechnol. 21, 41 46.
127. Wu, W., Wieckowski, S., Pastorin, G., Benincasa, M., Klumpp, C., Briand, J.P., Gennaro, R., Prato, M. Bianco, A. (2005). Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew. Chem. Int. Ed. Engl. 44, 6358 6362.
128. Yang, J., Chen, H., Vlahov, I.R., Cheng, J.X. Low, P.S. (2007). Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. J. Pharmacol. Exp. Ther. 321, 462 468.
129. Yano, J., Hirabayashi, K., Nakagawa, S. et al. (2004). Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res. 10, 7721 7726.
130. Yazdi, A.S., Palmedo, G., Flaig, M.J. et al. (2003). Mutations of the BRAF gene in benign and malignant melanocytic lesions. J. Invest. Dermatol. 121, 1160 1162.